Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Form 4 snapshot: On 07/29/2025 Immunome (IMNM) granted Chief Scientific Officer Jack Higgins an employee stock option for 196,000 common shares at a strike price of $10.60. The option expires on 07/28/2035, giving a standard 10-year term.
Vesting schedule: 25 % of the award vests on 07/29/2026; the remaining 75 % vests in equal monthly installments over the next 36 months, completing vesting by mid-2029.
Table I shows no purchases or sales of non-derivative shares, so Higgins’ direct common-stock position is unchanged. After the grant he beneficially owns 196,000 derivative securities, all held directly.
Investor takeaway: The filing records routine executive compensation; no immediate cash outlay occurred and potential dilution is limited to the new option pool.